{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Thyroid+Gland+Medullary+Carcinoma&page=2", "query": { "condition": "Metastatic Thyroid Gland Medullary Carcinoma", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Thyroid+Gland+Medullary+Carcinoma&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-25T13:49:04.376Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00098813", "title": "Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Thyroid Cancer", "Stage IV Follicular Thyroid Cancer", "Stage IV Papillary Thyroid Cancer" ], "interventions": [ { "name": "romidepsin", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "positron emission tomography", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2004-10", "completion_date": "2009-08", "has_results": true, "last_update_posted_date": "2014-05-28", "last_synced_at": "2026-06-25T13:49:04.376Z", "location_count": 1, "location_summary": "Commack, New York", "locations": [ { "city": "Commack", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00098813" }, { "nct_id": "NCT03587662", "title": "Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Kidney Medullary Carcinoma", "Metastatic Renal Cell Carcinoma", "SMARCB1 Negative", "Stage III Renal Cell Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8" ], "interventions": [ { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" }, { "name": "Ixazomib", "type": "DRUG" }, { "name": "Ixazomib Citrate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 30, "start_date": "2018-08-17", "completion_date": "2027-01-31", "has_results": false, "last_update_posted_date": "2026-01-09", "last_synced_at": "2026-06-25T13:49:04.376Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03587662" }, { "nct_id": "NCT03866382", "title": "Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Adenocarcinoma", "Bladder Clear Cell Adenocarcinoma", "Bladder Mixed Adenocarcinoma", "Bladder Neuroendocrine Carcinoma", "Bladder Small Cell Neuroendocrine Carcinoma", "Bladder Squamous Cell Carcinoma", "Chromophobe Renal Cell Carcinoma", "Collecting Duct Carcinoma", "Invasive Bladder Giant Cell Urothelial Carcinoma", "Invasive Bladder Lymphoepithelioma-Like Carcinoma", "Invasive Bladder Nested Urothelial Carcinoma", "Invasive Bladder Plasmacytoid Urothelial Carcinoma", "Invasive Bladder Sarcomatoid Urothelial Carcinoma", "Invasive Bladder Urothelial Carcinoma", "Kidney Medullary Carcinoma", "Large Cell Neuroendocrine Carcinoma", "Malignant Testicular Leydig Cell Tumor", "Malignant Testicular Sertoli Cell Tumor", "Metastatic Bladder Carcinoma", "Metastatic Bladder Clear Cell (Glycogen-Rich) Urothelial Carcinoma", "Metastatic Bladder Giant Cell Urothelial Carcinoma", "Metastatic Bladder Large Cell Neuroendocrine Carcinoma", "Metastatic Bladder Lipid-Rich Urothelial Carcinoma", "Metastatic Bladder Micropapillary Urothelial Carcinoma", "Metastatic Bladder Plasmacytoid Urothelial Carcinoma", "Metastatic Bladder Sarcomatoid Urothelial Carcinoma", "Metastatic Bladder Small Cell Neuroendocrine Carcinoma", "Metastatic Bladder Squamous Cell Carcinoma", "Metastatic Chromophobe Renal Cell Carcinoma", "Metastatic Kidney Medullary Carcinoma", "Metastatic Malignant Genitourinary System Neoplasm", "Metastatic Papillary Renal Cell Carcinoma", "Metastatic Penile Carcinoma", "Metastatic Prostate Small Cell Neuroendocrine Carcinoma", "Metastatic Sarcomatoid Renal Cell Carcinoma", "Metastatic Urethral Carcinoma", "Papillary Renal Cell Carcinoma", "Sarcomatoid Renal Cell Carcinoma", "Stage IV Bladder Cancer AJCC v8", "Stage IV Penile Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8", "Stage IV Urethral Cancer AJCC v8", "Stage IVB Prostate Cancer AJCC v8", "Urachal Adenocarcinoma", "Urethral Clear Cell Adenocarcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Cabozantinib S-malate", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 314, "start_date": "2019-05-13", "completion_date": "2027-02-28", "has_results": false, "last_update_posted_date": "2026-06-25", "last_synced_at": "2026-06-25T13:49:04.376Z", "location_count": 580, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Kingman, Arizona + 377 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03866382" }, { "nct_id": "NCT04467021", "title": "Cancer and Blood Pressure Management, CARISMA Study", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cardiovascular Disorder", "Chronic Kidney Disease", "Metastatic Renal Cell Carcinoma", "Metastatic Thyroid Gland Medullary Carcinoma", "Stage IV Renal Cell Cancer AJCC v8", "Stage IV Thyroid Gland Medullary Carcinoma AJCC v8", "Stage IVA Thyroid Gland Medullary Carcinoma AJCC v8", "Stage IVB Thyroid Gland Medullary Carcinoma AJCC v8", "Stage IVC Thyroid Gland Medullary Carcinoma AJCC v8" ], "interventions": [ { "name": "Best Practice", "type": "OTHER" }, { "name": "Blood Pressure Measurement", "type": "OTHER" }, { "name": "Clinical Management", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "ECOG-ACRIN Cancer Research Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2020-10-29", "completion_date": "2026-08-31", "has_results": false, "last_update_posted_date": "2026-06-18", "last_synced_at": "2026-06-25T13:49:04.376Z", "location_count": 25, "location_summary": "Creve Coeur, Missouri • St Louis, Missouri • The Bronx, New York + 18 more", "locations": [ { "city": "Creve Coeur", "state": "Missouri" }, { "city": "St Louis", "state": "Missouri" }, { "city": "The Bronx", "state": "New York" }, { "city": "The Bronx", "state": "New York" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04467021" }, { "nct_id": "NCT00019331", "title": "Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer", "Endometrial Cancer", "Head and Neck Cancer", "Liver Cancer", "Lung Cancer", "Melanoma (Skin)", "Pancreatic Cancer", "Testicular Germ Cell Tumor", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "ras peptide cancer vaccine", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "DetoxPC", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1997-10", "completion_date": "2007-05", "has_results": false, "last_update_posted_date": "2013-06-20", "last_synced_at": "2026-06-25T13:49:04.376Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00019331" }, { "nct_id": "NCT00068497", "title": "Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Anaplastic Thyroid Cancer", "Insular Thyroid Cancer", "Metastatic Parathyroid Cancer", "Recurrent Adenoid Cystic Carcinoma of the Oral Cavity", "Recurrent Basal Cell Carcinoma of the Lip", "Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Recurrent Lymphoepithelioma of the Nasopharynx", "Recurrent Lymphoepithelioma of the Oropharynx", "Recurrent Metastatic Squamous Neck Cancer With Occult Primary", "Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Recurrent Mucoepidermoid Carcinoma of the Oral Cavity", "Recurrent Non-small Cell Lung Cancer", "Recurrent Parathyroid Cancer", "Recurrent Salivary Gland Cancer", "Recurrent Squamous Cell Carcinoma of the Hypopharynx", "Recurrent Squamous Cell Carcinoma of the Larynx", "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity", "Recurrent Squamous Cell Carcinoma of the Nasopharynx", "Recurrent Squamous Cell Carcinoma of the Oropharynx", "Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Thyroid Cancer", "Recurrent Verrucous Carcinoma of the Larynx", "Stage III Follicular Thyroid Cancer", "Stage III Papillary Thyroid Cancer", "Stage III Salivary Gland Cancer", "Stage III Squamous Cell Carcinoma of the Hypopharynx", "Stage III Squamous Cell Carcinoma of the Larynx", "Stage III Verrucous Carcinoma of the Larynx", "Stage IIIB Non-small Cell Lung Cancer", "Stage IV Lymphoepithelioma of the Nasopharynx", "Stage IV Non-small Cell Lung Cancer", "Stage IV Squamous Cell Carcinoma of the Hypopharynx", "Stage IV Squamous Cell Carcinoma of the Nasopharynx", "Stage IVA Adenoid Cystic Carcinoma of the Oral Cavity", "Stage IVA Basal Cell Carcinoma of the Lip", "Stage IVA Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Stage IVA Follicular Thyroid Cancer", "Stage IVA Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Stage IVA Lymphoepithelioma of the Oropharynx", "Stage IVA Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Stage IVA Mucoepidermoid Carcinoma of the Oral Cavity", "Stage IVA Papillary Thyroid Cancer", "Stage IVA Salivary Gland Cancer", "Stage IVA Squamous Cell Carcinoma of the Larynx", "Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IVA Squamous Cell Carcinoma of the Oropharynx", "Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IVA Verrucous Carcinoma of the Larynx", "Stage IVA Verrucous Carcinoma of the Oral Cavity", "Stage IVB Adenoid Cystic Carcinoma of the Oral Cavity", "Stage IVB Basal Cell Carcinoma of the Lip", "Stage IVB Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Stage IVB Follicular Thyroid Cancer", "Stage IVB Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Stage IVB Lymphoepithelioma of the Oropharynx", "Stage IVB Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Stage IVB Mucoepidermoid Carcinoma of the Oral Cavity", "Stage IVB Papillary Thyroid Cancer", "Stage IVB Salivary Gland Cancer", "Stage IVB Squamous Cell Carcinoma of the Larynx", "Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IVB Squamous Cell Carcinoma of the Oropharynx", "Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IVB Verrucous Carcinoma of the Larynx", "Stage IVB Verrucous Carcinoma of the Oral Cavity", "Stage IVC Adenoid Cystic Carcinoma of the Oral Cavity", "Stage IVC Basal Cell Carcinoma of the Lip", "Stage IVC Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Stage IVC Follicular Thyroid Cancer", "Stage IVC Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Stage IVC Lymphoepithelioma of the Oropharynx", "Stage IVC Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Stage IVC Mucoepidermoid Carcinoma of the Oral Cavity", "Stage IVC Papillary Thyroid Cancer", "Stage IVC Salivary Gland Cancer", "Stage IVC Squamous Cell Carcinoma of the Larynx", "Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IVC Squamous Cell Carcinoma of the Oropharynx", "Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IVC Verrucous Carcinoma of the Larynx", "Stage IVC Verrucous Carcinoma of the Oral Cavity", "Thryoid Gland Nonmedullary Carcinoma", "Thyroid Gland Medullary Carcinoma", "Tongue Cancer", "Untreated Metastatic Squamous Neck Cancer With Occult Primary" ], "interventions": [ { "name": "gefitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 40, "start_date": "2003-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-14", "last_synced_at": "2026-06-25T13:49:04.376Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00068497" }, { "nct_id": "NCT00519896", "title": "Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Thyroid Cancer", "Stage IVA Follicular Thyroid Cancer", "Stage IVA Papillary Thyroid Cancer", "Stage IVB Follicular Thyroid Cancer", "Stage IVB Papillary Thyroid Cancer", "Stage IVC Follicular Thyroid Cancer", "Stage IVC Papillary Thyroid Cancer", "Thyroid Gland Medullary Carcinoma" ], "interventions": [ { "name": "sunitinib malate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2007-07", "completion_date": "2015-09", "has_results": true, "last_update_posted_date": "2017-04-25", "last_synced_at": "2026-06-25T13:49:04.376Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00519896" }, { "nct_id": "NCT01204476", "title": "Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gastrin-Producing Neuroendocrine Tumor", "Lung Carcinoid Tumor", "Metastatic Digestive System Neuroendocrine Tumor G1", "Pancreatic Glucagonoma", "Pancreatic Insulinoma", "Pancreatic Polypeptide Tumor", "Paraganglioma", "Recurrent Digestive System Neuroendocrine Tumor G1", "Recurrent Merkel Cell Carcinoma", "Recurrent Pancreatic Neuroendocrine Carcinoma", "Regional Digestive System Neuroendocrine Tumor G1", "Somatostatin-Producing Neuroendocrine Tumor", "Stage III Merkel Cell Carcinoma", "Stage IV Merkel Cell Carcinoma", "Thyroid Gland Medullary Carcinoma" ], "interventions": [ { "name": "Cixutumumab", "type": "BIOLOGICAL" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Octreotide Acetate", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2010-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2016-07-15", "last_synced_at": "2026-06-25T13:49:04.376Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01204476" }, { "nct_id": "NCT04106843", "title": "Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced Adrenal Gland Pheochromocytoma", "Locally Advanced Paraganglioma", "Metastatic Adrenal Gland Pheochromocytoma", "Metastatic Paraganglioma", "Metastatic Parathyroid Gland Carcinoma", "Pituitary Gland Carcinoma", "Somatostatin Receptor Positive", "Stage III Thyroid Gland Medullary Carcinoma AJCC v8", "Stage IV Thyroid Gland Medullary Carcinoma AJCC v8", "Stage IVA Thyroid Gland Medullary Carcinoma AJCC v8", "Stage IVB Thyroid Gland Medullary Carcinoma AJCC v8", "Stage IVC Thyroid Gland Medullary Carcinoma AJCC v8", "Unresectable Adrenal Gland Pheochromocytoma", "Unresectable Paraganglioma" ], "interventions": [ { "name": "Lutetium Lu 177 Dotatate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2019-06-13", "completion_date": "2020-09-03", "has_results": false, "last_update_posted_date": "2020-09-07", "last_synced_at": "2026-06-25T13:49:04.376Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04106843" }, { "nct_id": "NCT00118248", "title": "Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Thyroid Cancer", "Stage IV Follicular Thyroid Cancer", "Stage IV Papillary Thyroid Cancer", "Thyroid Gland Medullary Carcinoma" ], "interventions": [ { "name": "tanespimycin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2004-12", "completion_date": "2012-04", "has_results": true, "last_update_posted_date": "2017-02-15", "last_synced_at": "2026-06-25T13:49:04.376Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00118248" } ] }